Pharmaceutical Keeping up the recent momentum of positive news on its CNS drug pimavanserin, Acadia Pharmaceuticals today presented top-line results from its Phase III HARMONY study at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, December 4 -7, 2019 in San Diego, California, sending the firm’s share up 10% pre-market. 5 December 2019